We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Tests to Speed Asthma Drug Clinical Trials

By LabMedica International staff writers
Posted on 18 Oct 2012
Print article
Molecular signals or biomarkers will be identified that are predictive of chronic inflammatory responses in allergic asthmatic adults.

The Center of Excellence for the Prevention of Organ Failure (PROOF Center; Vancouver, BC, Canada) and AllerGen NCE (Hamilton, ON, Canada) expect to complete the development and validation of a biomarker panel which, by early 2014, will predict an asthmatic individual's response to allergen exposure, and that can diagnose a late allergic response. Blood samples will be obtained from the AllerGen Clinical Investigator Collaborative (CIC) and using the expertise of the PROOF Centre, investigators will identify the predictive biomarkers. The discovery of novel biomarkers will ultimately allow for the effective monitoring of promising therapeutics for allergic asthma.

Individuals with allergic asthma respond differently to exposure to allergens such as pollen, mites, or molds. While some develop an isolated early (resolving quickly) response, others go on to develop a late (i.e., ongoing and more severe) response, the latter characterized by severe inflammation of the airways that can only be partly reversed by existing drugs.

"Such biomarkers, implemented via a simple blood test, will identify subjects who are late asthmatic responders so that they can be pre-selected for clinical trials that examine how effective new pharmacological interventions are in attenuating inflammatory responses to allergen exposure," said Dr. Scott Tebbutt, CSO Officer of the PROOF Center. "By speeding up the selection process, these blood tests will also lower the cost of recruiting asthmatic subjects into clinical trials."

Today, over 50% of Canadian families are directly or indirectly affected by asthma and allergic diseases. Allergic diseases place tremendous psychosocial and economic burdens on both Canadians and the healthcare system, costing up to CAD 15 billion annually in emergency department visits, prescribed medications, and productivity losses at school and work.

Related Links:

Center of Excellence for the Prevention of Organ Failure
AllerGen NCE



New
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Unit-Dose Packaging solution
HLX
New
PoC Testing Device
QuikRead
New
Hemacytometer Cover Glasses
Propper Hemacytometer Cover Glasses

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The discovery of a new blood group has solved a 50- year-old mystery (Photo courtesy of 123RF)

Newly Discovered Blood Group System to Help Identify and Treat Rare Patients

The AnWj blood group antigen, a surface marker discovered in 1972, has remained a mystery regarding its genetic origin—until now. The most common cause of being AnWj-negative is linked to hematological... Read more

Microbiology

view channel
Image: The inbiome molecular culture ID technology has received FDA breakthrough device designation (Photo courtesy of inbiome)

Revolutionary Molecular Culture ID Technology to Transform Bacterial Diagnostics

Bacterial infections pose a major threat to public health, contributing to one in five deaths worldwide. Current diagnostic methods often take several days to provide results, which can delay appropriate... Read more

Pathology

view channel
Image: Confocal- & laminar flow-based detection scheme of intact virus particles, one at a time (Photo courtesy of Paz Drori)

Breakthrough Virus Detection Technology Combines Confocal Fluorescence Microscopy with Microfluidic Laminar Flow

Current virus detection often relies on polymerase chain reaction (PCR), which, while highly accurate, can be slow, labor-intensive, and requires specialized lab equipment. Antigen-based tests provide... Read more

Industry

view channel
Image: The GeneXpert system’s fast PCR Xpert tests can fight AMR and superbugs with fast and accurate PCR in one hour (Photo courtesy of Cepheid)

Cepheid Partners with Fleming Initiative to Fight Antimicrobial Resistance

Antimicrobial resistance (AMR) is responsible for over one million deaths globally each year and poses a growing challenge in treating major infectious diseases like tuberculosis, Escherichia coli (E.... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.